CHE Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

658.97M

+2.97%

7.067

+3.48%

666.23M

+2.98%

5.993

+6.45%

663.87M

+7.28%

5.890

+37.94%

Estimates Revision

The market is revising Upward the revenue expectations for Chemed Corporation (CHE) for FY2025, with the revenue forecasts being adjusted by 0.02% over the past three months. During the same period, the stock price has changed by 4.12%.

Revenue Estimates for FY2025

Revise Upward

+0.02%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.18%

In Past 3 Month

Stock Price

Go Up

+4.12%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast CHE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CHE is 574.25 USD with a low forecast of 550.00 USD and a high forecast of 595.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

550.00

Averages

574.25

High

595.00

Current: 0.000

Low

550.00

Averages

574.25

High

595.00

RBC Capital

Outperform -> NULL

downgrade

$589 -> $572

2025-11-10

Reason

RBC Capital

Price Target

$589 -> $572

2025-11-10

downgrade

Outperform -> NULL

Reason

RBC Capital lowered the firm's price target on Chemed to $572 from $589 and keeps an Outperform rating on the shares. The company reported solid Q3 results and reaffirmed full-year guidance, the analyst tells investors in a research note. While adjusted EBITDA in both VITAS and Roto-Rooter was slightly below Street consensus, the print was in line with the management's expectations and serves as reaffirmation of its confidence in navigating challenges, RBC added.

BofA

analyst

Buy

downgrade

$610 -> $595

2025-09-10

Reason

BofA

analyst

Price Target

$610 -> $595

2025-09-10

downgrade

Buy

Reason

BofA lowered the firm's price target on Chemed to $595 from $610 and keeps a Buy rating on the shares. While hospital fundamentals should remain solid in the second half, the firm is concerned that the policy and reimbursement environment will be more negative compared to recent years, says the analyst, who prefers post-acute over hospitals as the least exposed to the upcoming cuts given this backdrop. The firm is updating estimates and price targets for several companies in its health care facilities coverage.

Jefferies

Hold

Buy

upgrade

$490 -> $550

2025-09-02

Reason

Jefferies

Price Target

$490 -> $550

2025-09-02

upgrade

Hold

Buy

Reason

Jefferies upgraded Chemed to Buy from Hold with a price target of $550, up from $490. The company's fiscal 2026 reimbursement, particularly in Florida, came in more favorable than expected, the analyst tells investors in a research note. The firm believes this positions Chemed for 2026 EBITDA at the high end of the current Street range. Better than expected reimbursement and "aggressive" share buybacks should drive the stock's multiple higher in the near-term, contends Jefferies.

Jefferies

Hold

initiated

$500

2025-07-25

Reason

Jefferies

Price Target

$500

2025-07-25

initiated

Hold

Reason

Jefferies initiated coverage of Chemed with a Hold rating and $500 price target. The firm likes the hospice space and Chemed's track record of execution and capital allocation, but says the recent issues related to the Medicare cap, particularly in Florida, will likely carry over into 2026. These will limit Chemed's ability to achieve the consensus 2026 EBITDA estimates, the analyst tells investors in a research note.

BofA

Buy

downgrade

$708 -> $650

2025-06-30

Reason

BofA

Price Target

$708 -> $650

2025-06-30

downgrade

Buy

Reason

BofA lowered the firm's price target on Chemed to $650 from $708 and keeps a Buy rating on the shares. Chemed on Friday said that the Medicare cap will be a $20M, or 4%, headwind in 2025, which is not a surprise given the Q1 disclosures, but admissions in Florida were weaker in April and May, while Roto-Rooter residential was worse than expected, the analyst tells investors in a research note. While the stock will be pressured on the worse 2025, BofA likes the longer-term fundamentals for both Vitas and Roto.

RBC Capital

Ben Hendrix

Outperform

downgrade

$674 -> $640

2025-06-30

Reason

RBC Capital

Ben Hendrix

Price Target

$674 -> $640

2025-06-30

downgrade

Outperform

Reason

RBC Capital analyst Ben Hendrix lowered the firm's price target on Chemed to $640 from $674 and keeps an Outperform rating on the shares. The firm is disappointed to see Medicare cap limitations weigh on the 2025 outlook, though it is also encouraged by VITAS' new CON, which should help the company maintain strong positioning in an increasingly competitive FL market, the analyst tells investors in a research note. RBC adds that headwinds at Roto-Rooter continue with an unanticipated decline in residential volume, which more than offset improving commercial trends.

Valuation Metrics

The current forward P/E ratio for Chemed Corp (CHE.N) is 16.91, compared to its 5-year average forward P/E of 23.84. For a more detailed relative valuation and DCF analysis to assess Chemed Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

23.84

Current PE

16.91

Overvalued PE

26.30

Undervalued PE

21.39

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

16.11

Current EV/EBITDA

11.60

Overvalued EV/EBITDA

17.66

Undervalued EV/EBITDA

14.57

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

3.31

Current PS

2.25

Overvalued PS

3.67

Undervalued PS

2.95

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 158.47% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CHE News & Events

Events Timeline

No data

News

9.5

01-02Globenewswire

Chemed to Release Q4 2025 Financial Results on February 25, 2026

9.5

01-02Newsfilter

Chemed Corporation Schedules Q4 2025 Earnings Release for February 25, 2026

8.0

2025-12-18Newsfilter

Chemtrade Logistics Declares $0.0575 Cash Distribution per Unit for December 2025

People Also Watch

Frequently Asked Questions

What is Chemed Corp (CHE) stock price today?

The current price of CHE is 449.18 USD — it has increased 2.25 % in the last trading day.

What is Chemed Corp (CHE)'s business?

Chemed Corporation is engaged in purchasing, operating, and divesting subsidiaries in diverse business activities. The Company's segment includes VITAS and the Roto-Rooter. The VITAS segment provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers. It provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. The Roto-Rooter segment provides plumbing, drain cleaning, excavation, water restoration and other related services to residential and commercial customers. The Roto-Rooter services are provided through a network of Company-owned branches, independent contractors and franchisees. The Company's water restoration services involve the remediation of water and humidity after a flood and are provided to both commercial and residential customers.

What is the price predicton of CHE Stock?

What is Chemed Corp (CHE)'s revenue for the last quarter?

Chemed Corp revenue for the last quarter amounts to 624.90M USD, increased 3.09 % YoY.

What is Chemed Corp (CHE)'s earnings per share (EPS) for the last quarter?

Chemed Corp. EPS for the last quarter amounts to 4.46 USD, decreased -10.80 % YoY.

What changes have occurred in the market's expectations for Chemed Corp (CHE)'s fundamentals?

How many employees does Chemed Corp (CHE). have?

Chemed Corp (CHE) has 15695 emplpoyees as of January 09 2026.

What is Chemed Corp (CHE) market cap?

Today CHE has the market capitalization of 6.22B USD.